CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The MA40 trial, a double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor has closed to further accrual as the accrual target of 250 study participants enrolled.
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
At the recent annual meeting of the Austrian Working Group for Gynaecological Oncology in the Austrian Society for Gynecology and Obstetrics the Ernst Wertheim Award was presented to Dr Marie Plante, the CCTG CX5 study lead and Gynecologic Oncologist at CHU de Quebec, Canada.
CCTG has been working closely with our NCI/CTSU counterparts to develop the process and workflow for investigator and research staff registrations. Here is what is understood as we move toward implementation:
1. All individuals that are registered at the time of the changeover will be grandfathered.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative volunteer for the Investigational New Drug (IND) Committee.
